Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senate HHS Approps Chair Harkin Looking At FDA Rules On Women In Trials

Executive Summary

The representation of women in clinical trials will be a likely hearing topic for the Senate Appropriations/Labor, HHS & Education Subcommittee under incoming Chairman Harkin (D-Iowa).

You may also be interested in...



Recent Drug Withdrawals Had Greater Health Risks For Women - GAO Report

Eight of 10 prescription drugs withdrawn from the market since Jan. 1, 1997 presented more significant health risks for women than men, a General Accounting Office report finds.

FDA Adverse Event Monitoring "Flaws" Highlighted In GAO Transition Report

Improving the monitoring of drug adverse events is one of FDA's main challenges, a General Accounting Office transition report on HHS indicates.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS038006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel